At the Sean M. Healey & AMG Center for ALS, compassionate clinical care converges with cutting-edge research every day. The laboratories at the Charlestown Navy Yard are humming with investigators researching the latest breakthroughs in ALS and bringing us closer to a cure.
Rebecca Gillani, MD, PhD, a physician investigator in the Department of Neurology at Massachusetts General Hospital and an Instructor in Neurology at Harvard Medical School, is the lead author of a recently published paper in Brain, Behavior, and Immunity; Instability of Excitatory Synapses in Experimental Autoimmune Encephalomyelitis and the Outcome for Excitatory Circuit Inputs To Individual Cortical Neurons.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and Rapa Therapeutics have announced the first participant enrolled in the Expanded Access to RAPA-501 Protocol (EAP
Researchers from Massachusetts General Hospital and Boston Children's Hospital created a connectivity map of a brain network they propose is critical to human consciousness.
Researchers at Massachusetts General Hospital and Boston Children's Hospital created a connectivity map of a brain network that they propose is critical to human consciousness.
The Sean M. Healey & AMG Center for ALS in collaboration with the Northeast ALS Consortium (NEALS) is thrilled to announce the completion of enrollment for Regimen G of the HEALEY ALS Platform Trial
The Healey & AMG Center for ALS at Massachusetts General Hospital in collaboration with Prilenia Therapeutics B.V is thrilled to announce the enrollment of the first participant
A new clinical indicates that conversational interactions—a core component of human connections—can stimulate different brain functions among socially isolated older adults, even when the interactions are Internet-based.
In a study of 30 active-duty United States SOF personnel, researchers found that increased blast exposure was associated with structural, functional, and neuroimmune changes to the brain and a decline in health-related quality of life.
Enrollment is now complete for Regimen F evaluating ABBV-CLS-7262, an investigational product being developed by Calico Life Sciences LLC (Calico) in collaboration with AbbVie.
The Patient Gateway provides secure online access to your health information whenever you need it. Check upcoming appointments, communicate with your doctor’s office, review medications and pay medical bills—all seamlessly online 24/7.
